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CAPSULE SUMMARY 36 
 37 
Maternal use of acid-suppressive medications was associated with an increased risk of 38 
asthma in children.  Further research is now needed to clarify if this is a true risk or if it 39 


























To the Editor 64 
 65 
Acid suppressive medications, such as H2-receptor antagonists (H2RA) and proton pump 66 
inhibitors (PPI), are the main treatment options for dyspepsia and gastroesophageal reflux 67 
disease.  These are common problems in pregnancy.1 Recently, concerns have  been raised 68 
that prenatal exposure to these medications may increase the risk of allergic disease in the 69 
offspring.1 Dehlink and colleagues were the first to report these associations, proposing that 70 
use of acid-suppressive medications in pregnancy may increase the risk of allergic disease in 71 
the offspring through interference with maternal digestion of labile antigens, thereby 72 
increasing the amount of allergen to which the fetus is exposed.  PPI use has also been 73 
linked to changes in the intestinal microbiota composition,2 which may also increase the risk 74 
of Th2-mediated conditions, such as asthma and allergy. Dehlink and colleagues therefore 75 
proposed that acid-suppressive medications could operate through one or both of these 76 
mechanisms, inducing a Th2 cytokine pattern in mothers, which  could then cross the fetal 77 
membrane and induce sensitization of fetal immune cells to food and airborne allergens prior 78 
to birth.1 79 
 80 
An increasing number of studies have now investigated the impact of prenatal exposure to 81 
acid-suppressive medications on the risk of allergic disease in the offspring, but with 82 
inconsistent results.1,3-9 In order to obtain a clearer appreciation of the evidence base, we 83 
undertook a systematic review and meta-analysis of these studies. We were also interested 84 
in clarifying whether use of the sub-types of acid-suppressive medications, namely H2RA 85 
and PPIs, was associated with asthma/allergy; and whether any associations uncovered 86 
varied by time (trimester), dose, and frequency of exposure. 87 
 88 
We included analytical epidemiological studies (i.e. cohort, case-control, and cross-sectional 89 
studies). We excluded reviews, case studies and case series, and animal studies. All women 90 
during preconception and pregnancy and their offspring who were 17 years were eligible for 91 
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inclusion. Our primary outcomes were objectively defined asthma, atopic dermatitis/eczema, 92 
allergic rhinitis or hay fever, food allergy, urticarial and anaphylaxis;  and atopic sensitization 93 
as defined either by skin prick test or raised antigen specific IgE (see description of 94 
secondary outcomes in the Online Repository).  95 
 96 
To identify relevant studies, we searched 11 electronic databases and searched databases 97 
of ongoing studies and conference abstracts (see details in the Online Repository). We also 98 
contacted experts in the field to identify additional studies and any ongoing study. We 99 
developed a detailed search strategy in MEDLINE, which was then adapted for searching 100 
other databases (Table E1 in the Online Repository). All databases were searched from 101 
inception to the end of 2015, with no language restrictions. Two reviewers (RD and BN) 102 
independently screened all titles and/or abstracts; screened full texts of potentially eligible 103 
studies; extracted study data onto a customized data extraction form; and quality appraised 104 
all studies using the Effective Public Health Practice Project tool. Any discrepancies in the 105 
process were resolved by discussion or a third reviewer (NM) arbitrated. We graded key 106 
components from which we derived an overall grading for each study as strong, moderate, or 107 
weak (see Tables E2 and E3 in the Online Repository).  108 
 109 
We employed random-effects meta-analysis to quantify the pooled effect estimates for 110 
reasonably homogeneous studies. Meta-analysis was possible with studies on risk of 111 
asthma, but not for other outcomes due to insufficient number of studies. Dosage, trimester, 112 
and frequency of exposure to acid-suppressive medications were differentially reported 113 
across studies, hence we were unable to pool studies on these exposures. We quantified the 114 
level of heterogeneity between studies using the I2 statistic (values near zero indicate good 115 
homogeneity across studies). Meta-analyses were undertaken using Stata 14, College 116 
Station, TX: StataCorp LP. See the Online Repository for a fuller description of our approach 117 




Of the 3282 records identified from our searches, eight studies1,3-9 met our inclusion criteria 120 
(see Figure E1 in the Online Repository). Key characteristics of the studies are presented in 121 
Table E2 in the Online Repository. Six studies were graded as strong and two as moderate. 122 
In pooled analysis, use of any acid-suppressive medications (RR 1.36, 95%CI 1.16-1.61, 123 
I2=87·6%), H2RA (HR 1.46, 95%CI 1.29-1.65, I2=15·3%), and PPI (HR 1.30, 95%CI 1.07-124 
1.56, I2=45·2%) were associated with an increased risk of asthma (Figures 1 and 2). Results 125 
of sensitivity analyses are given in the Online Repository. Two studies that considered other 126 
allergic disorders both reported an increased risk amongst offspring of mothers using any 127 
acid-suppressive medications, H2RA, and PPIs compared to the offspring of non-using 128 
mothers1,7 (see Table E2 in the Online Repository). By applying the GRADE approach, we 129 
graded the evidence regarding the risk of asthma as moderate, but evidence regarding other 130 
allergic outcomes as very low (see Table E4 in the Online Repository). The Eggers test (to 131 
evaluate publication bias and small-study effect) for the association between use of any acid-132 
suppressive medications and risk of asthma showed P=0.415. 133 
 134 
Our literature search was comprehensive. We had no language restriction, reproducible 135 
search strategies, and we applied rigorous review processes, which were enhanced by 136 
publishing and registering a detailed protocol prior to undertaking the review.10 The degree of 137 
heterogeneity between studies was low; the only case of high heterogeneity was due to 138 
differences in the definition of the exposure. In the course of our literature search, we found a 139 
recent systematic review from Google Scholar, published in Chinese in a local journal.11 Five 140 
studies were included in that review and were meta-analyzed. On translation to English, we 141 
found that the systematic review process was deficient in many aspects, including: lack of 142 
information about quality assessment, data extraction, or the number of reviewers involved; 143 
unclear decisions regarding meta-analysis decisions (whether fixed-effect or random-effects 144 





Animal models and studies undertaken in adults suggest that acid-suppressive medications 148 
may interfere with peptide digestion, thereby inducing a Th2 cytokine dominance, which may 149 
result in subsequent sensitization of the immune system.1  Such interference may increase 150 
the amount of allergen the fetus is exposed to via the placenta, thereby resulting in 151 
sensitization and subsequent development of allergic disorders and asthma.1 Our findings of 152 
increased risk may reflect a true risk or may be explained by residual confounding and/or 153 
confounding by indication. Of note is that none of the studies adjusted for the full panel of 154 
known confounders in these associations. While we cannot recommend any changes to the 155 
use of acid-suppressive medications by expectant mothers, further research is needed, 156 
particularly through mounting pharmacovigilance studies, which may prove more ethically 157 
acceptable and feasible than initiating randomized controlled clinical trials.  158 
 159 
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FIGURE LEGENDS 197 
Figure 1:  198 
Meta-analysis of studies investigating the association between maternal use of any acid-199 
suppressive medication during pregnancy and the risk of asthma in the offspring. RR 200 
represents the risk ratio of association. PANEL A estimates by study design; PANEL B  201 
estimates by study design, excluding Yitshak-Sade 2015. Population represents the number 202 




Figure 2: 205 
Meta-analysis of studies investigating the association between maternal use of H2- receptor 206 
antagonists (H2RA  PANEL A) and proton pump inhibitors (PPI  PANEL B) during 207 
pregnancy and the risk of asthma in the offspring. HR represents the hazard ratio of 208 
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TABLE E1: MEDLINE Search Strategies used to Identify Studies and Adapted in Searching 
other Databases 
1. exp Proton Pump Inhibitors/ OR *Gastroesophageal Reflux/ OR exp Anti-Ulcer Agents/ OR exp 
Histamine H2 Antagonists/ OR *Helicobacter Infections/  
2. exp Antacids/ OR antacid.mp.  
3. exp Aluminum Hydroxide/ae, tu [Adverse Effects, Therapeutic Use]  
4. magnesium carbonate.mp.  
5. magnesium trisilicate.mp.  
6. hydrotalcite.mp.  
7. Alginates.mp. OR exp Alginates/  
8. Omeprazole/  
9. Lansoprazole/  
10. Esomeprazole/  
11. Rabeprazole/  
12. pantoprazole.mp.  
13. Cimetidine/  
14. Famotidine/  
15. Nizatidine/  
16. Ranitidine/  
17. OR/ 1-16  
18. exp pregnancy trimesters/  
19. pregnancy/  
20. antenatal.mp  
21. Pregnancy Trimester, Third/ or exp Pregnancy/ or Pregnancy Trimester, First/ or Pregnancy Trimester, 
Second/ or Pregnancy Trimesters/ or pregnancy.mp.  
22. exp Asthma/  
23. asthma.mp.  
24. wheez*.mp.  
25. exp Bronchial Hyperreactivity/  
26. airway hyperreactivity.mp.  
27. bronchial disorder.mp.  
28. lung function.mp.  
29. respiratory function.mp.  
30. ventilatory function.mp.  
31. airway function.mp.  
32. Vital Capacity/  
33. Forced Expiratory Volume/  
34. Peak Expiratory Flow Rate/  
35. peak expiratory flow.mp.  
36. exp hypersensitivity/  
37. exp dermatitis, allergic contact/  
38. exp hypersensitivity, immediate/  
39. anaphylaxis/  
40. conjunctivitis, allergic/  
41. dermatitis, atopic/  
42. exp food hypersensitivity/  
43. exp respiratory hypersensitivity/  
44. exp rhinitis, allergic/  
45. exp urticaria/  
46. angioedema/  
47. eczema/  
48. allergy.mp.  
49. atopy.mp.  
50. OR/ 22-49  
51. Limit 50 to all child (0-18 years)  
52. OR/ 18-21  




Table E2: Main characteristics, key results, and overall risk of bias assessment of the studies investigating the association 







N (maternal-child; source 











Outcome studied and 
assessment method 
 
Occurrence measure(s) and 
approach to statistical 
analysis 
 































Ascertained from the 
Aarhus University 
Prescription Database. 
Studied use of PPI, 
H2RA; their dosages 
(PPI: 28 pills; >28 pills; 
H2RA: 20 pills; >20 












Asthma: having a 




visit plus asthma 
diagnosis OR 
dispensations record 
for of anti-asthmatic 
medication 
Ascertained 









The authors stated they estimated 
incidence rate ratio (IRR) for the 
associations using Cox 
proportional hazards regression. 
As the Cox model estimates the 
hazard function, the correct 
measure here should be hazard 
ratio (HR). Adjusted for year of 
birth, county, gender, gestational 
age, birth order, maternal age, 
maternal smoking, maternal 
asthma, delivery mode, and 




PPI: (1.41, 1.27 to 1.56); 28 
pills (1.20, 1.01 to 1.43); >28 
pills (1.54 , 1.36 to 1.75) 
H2RA: (1.47, 1.32 to 1.65); 20 
pills (1.44, 1.06 to 1.95); >20 
pills (1.48, 1.31 to 1.67) 
Trimester (i.e. use of PPI or 
H2RA): 1
st




























Ascertained from the 
Medical Birth Register. 
Studied use of any ASM, 
including PPI, H2RA, 
and other drugs used for 
peptic ulcer and gastro-
esophageal reflux 
disease. Also considered 
the trimester of exposure 
(1
st
 trimester; late 
pregnancy) 
Allergy: ever 
hospitalized for an 
allergic disease 
(food allergy, atopic 
dermatitis, allergic 
rhinitis, anaphylaxis) 


















coded using the 
ICD-9 and 10 
Odds ratio (OR) using the Mantel-
Haenszel procedure; 95% CI 
confidence intervals calculated 
using the Miettinens test method. 
Adjusted for year of birth, parity, 




Any ASM and allergy: (1.43, 
1.29 to 1.59); 1
st
 trimester (1.38, 
1.22 to 1.57); Later pregnancy 
(1.34, 1.11 to 1.63) 
Any ASM and asthma: (1.51, 
1.35 to 1.69) 
H2RA and allergy: (1.41, 1.16 
to 1.70) 
PPI and allergy: (1.46, 1.27 to 
1.66) 
Other ASM: (1.29, 1.04 to 1.60) 
Strong 





















14 years of 
follow-up. 




Ascertained from the 
CPRD database. Studied 
use of any ASM, 
including PPI, H2RA, 
and use of other 
antacids. Also 









Asthma: received a 
diagnosis of asthma 
and was prescribed 
any asthma 
medications at least 
3 times within 12 
months after the firs 
diagnosis date 
Ascertained 
from the CPRD 
database. 
Asthma cases 
coded using the 
Read coding 
system 
OR using conditional logistic 
regression. Adjusted for gender, 
birth order, maternal age at birth, 









 trimester (1.01, 0.79 to 
2.08); 3
rd
 trimester (1.29, 1.03-
1.62) 
PPI or H2RA: (1.72, 1.00 to 
2.07); 
PPI: (2.76, 0.93 to 8.17) 
H2RA: (1.56, 0.85-2.90) 
Other ASM: (1.16, 1.95 to 1.42) 
Strong 
 






of the Swedish 
Medical Birth 




685015 2-6 years Ascertained from the 
Swedish Medical Birth 
Register. Studied use of 






Asthma: having at 









OR using the Mantel-Haenszel 
procedure; 95% CI confidence 
intervals calculated using the 
Miettinens test method. Adjusted 
for year of birth, maternal age, 
parity, smoking, BMI, and use of 









trimester of pregnancy: (1.60, 
1.40 to 1.76) 
Moderate 

































5.5 years Ascertained from the 
University of Groningen 
IADB.nl pharmacy 
prescription database 
using ATC codes. 
Studied use of any ASM 
and dosage (defined 
daily doses [DDD]) of 
use  0-14 DDD; >14 
DDD 
Asthma: having at 
least 2 prescriptions 
for asthma 
medication during 6 









coded using the 
ATC coding 
system 
OR using conditional logistic 
regression. Adjusted for maternal 
age at birth in the non-sibling 
case-control analysis, but not in 
the sibling case-control analysis as 
that variable was not a confounder 
in the latter analysis. Other factors 
 maternal asthma, sex of child, 
sequence of birth, and use of ASM 
by child were tested a priori as 
confounders but did not indicate 
any confounding role, hence were 





Any ASM: (1.85, 1.07 to 3.19) 
0-14 DDD: (1.19, 0.61 to 2.31) 




Any ASM: (1.52, 1.11 to 2.10) 
0-14 DDD: (1.18, 0.73 to 1.91) 
>14 DDD: (1.89, 1.24 to 2.88) 
Moderate 



















Ascertained from the 
University of Groningen 
IADB.nl pharmacy 
prescription database 
using ATC codes. 
Studied use of PPI or 
H2RA; PPI only; H2RA 
only; dosages (0-15, >15 









Asthma: 2 inhaled 
steroid prescription 
within 12 months 
Atopic dermatitis: 
!2 prescriptions for 
ointment containing 




Allergic rhinitis: !2 
prescriptions for 
nasal steroids within 










coded using the 
ATC coding 
system 
HR using Cox proportional hazard 
regression. Adjusted for year of 
birth, sex of child, use of ASM by 
child, maternal age at birth, 
maternal use of systemic 








H2RA or PPI: (1.57, 1.20 to 
2.05) 
0-15 DDD: (1.37, 0.84 to 2.25) 









 trimester: (1.32, 0.77 to 2.25) 
H2RA: (1.93, 1.25 to 3.00) 
PPI: (1.35, 0.94 to 1.94) 
 
Strong 











11010 Maximum of 
6 years 
follow-up 
Ascertained from The 
Health Improvement 
Network database using 
Read codes. At least one 
prescription of ASM (PPI, 
H2RA) during 
pregnancy. Also 











HR using Cox proportional hazard 
regression. Adjusted for maternal 
primary care physician visits pre 
and during pregnancy, maternal 
asthma, maternal comorbidities, 
maternal use of nonsteroidal anti-
inflammatory drugs, antibiotics, 
(HR,!95%!CI));!reference!is!non-
use.!
H2RA: Anytime (1.32, 1.05 to 
1.64); 1
st
 trimester (1.15, 0.77 to 
1.72); 2
nd
 trimester (1.75, 1.25 to 
2.47); 3
rd
 trimester (1.20, 0.93 to 
1.54); all three trimesters (1.26, 
Strong 








three trimesters).  
antihistamines during pregnancy, 
sex of child 
0.51 to 3.08) 
PPI: Anytime (1.03, 0.76 to 
1.40); 1
st
 trimester (1.07, 0.76 to 
1.51); 2
nd
 trimester (1.11, 0.60 to 
2.05); 3
rd
 trimester (0.69, 0.36 to 
1.30); all three trimesters (0.73, 
0.23 to 2.31) 
Yitshak-Sade 








91428 3-13 years 
follow-up 
Ascertained from the 
Clalit Health Services 
HMO medication 
dispensing registry. 
Maternal use of H2RA or 
PPI 2 months prior and 
during pregnancy. 
Studied use of H2RA; 
PPI; trimester of 
exposure; and DDD 
Asthma: 
hospitalization for 
asthma or had 
recurrent wheeze 
diagnosis. Classified 
using the ICD-9 
Ascertained 





Risk ratio (RR) using generalized 
estimating equations. Adjusted for 
maternal allergy or asthma, 
maternal age, infertility treatment, 
prenatal care, gestational age at 
birth, cesarean section birth, birth 
weight, child sex, year of birth, 
child use of ASM 2 years, 
maternal use of antibiotics, 
nonsteroidal anti-inflammatory 





H2RA or PPI: Anytime (1.09, 
1.01 to 1.17) 
<10 DDD: (1.05, 0.94 to 1.17);  
10-20 DDD: (1.07, 0.96 to 1.18); 
>20 DDD: (1.12, 1.06 to 1.18) 
1
st
 trimester: (1.08, 0.97 to 1.21) 
2
nd
 trimester: (1.11, 0.93 to 1.32) 
3
rd
 trimester: (0.99, 0.82 to 1.20) 
H2RA: (1.06, 0.97 to 1.15) 
PPI: (1.10, 0.98 to 1.22) 
Strong 
Abbreviations: ASM  Acid-suppressive medications; ATC  Anatomical Therapeutic Chemical; GP  General Practitioner; ICD-10; - International 





Table E3: Quality assessment of the studies investigating the association between maternal use of acid-suppressive medications 
during pregnancy and risk of asthma and allergy in the offspring 
 
Reference; country Overall risk of 
bias assessment 
Risk of bias assessment for study components 




Selection bias Confounding 
Andersen et al 2012; Denmark 
 
Strong Strong Strong Strong Strong Strong 
Dehlink et al 2009; Sweden 
 
Strong Strong Strong Strong Strong Moderate 
Hak et al 2013;United Kingdom 
 
Strong Strong Strong Strong Strong Moderate 
Källén et al 2013; Sweden 
 
Moderate Strong Moderate Moderate Moderate Moderate 
Mulder et al 2013; The Netherlands 
 
Moderate Strong Strong Moderate Moderate Weak 
Mulder et al 2014; The Netherlands 
 
Strong Strong Strong Moderate Strong Strong 
Soriano et al 2015; United Kingdom 
 
Strong Strong Moderate Strong Strong Moderate 
Yitshak-Sade et al 2015; Israel 
 
Strong Strong  Strong Moderate  Moderate  Strong  
 
The overall risk assessment was based on the component risk assessments (i.e., on the suitability of the study design for the research question, validity of exposure and 
outcome assessments, potential for selection bias, adjustment for confounding factors).
Table E4: GRADE evidence profile for systematic review and meta-analysis of observational analytic epidemiologic studies on the association 
between maternal use of acid-suppressive medications during pregnancy and risk of asthma and allergy in the offspring 
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 Any ASM ( RR 1.36, 
95% CI 1.16 to 1.61); 
H2RA (HR 1.46, 95% 
CI 1.29 to 1.65); 
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All studies were registry-based studies derived from population-based healthcare registers or general practitioner database 
2
Overall, estimates of the test of heterogeneity across studies was low. The initial observed high heterogeneity in the pooled estimates was explained by pooling together 
studies on any ASM and H2RA/PPI; but the heterogeneity was removed after excluding studies on H2RA/PPI from the pooled data  
3
Only one study evaluated this outcome, hence consistency across studies and precision of the pooled overall estimated could not be evaluated 
4
Each study calculated the risk estimate using different measures (hazard or odds ratios), which did not allow pooling of the studies 
5
Although pooled estimates could not be calculated from the studies because of different measures used to estimate risk effects across studies, the estimates provided in each 
study were precise 
6It is unlikely that we had missed any eligible study for inclusion: with high sensitive search strategies, we searched 11 leading medical electronic databases, contacted experts 
in the field, and searched abstract and ongoing studies databases for additional references. Eggers test for small-study effect for the pooled estimate was statistically non-
significant 
7
It is plausible that confounding by indication, residual confounding, or other unmeasured confounding factors could have influenced these observations. Data on use of ASM 
across studies were based on either prescription or dispensed medication, hence actual use was not ascertained. Given some inconsistency in reporting dosage and trimester 












 Outcome Baseline risk 
of outcome 
(proportion) 







Dehlink et al 2009 
 
Any ASM Asthma 0.037 Reported in the same paper 
(Dehlink et al 2009) 
 
1.51 (1.35 to -1.69)  
 






1.48 (1.33 to 1.65) 




1.23 (1.01 to 1.51) 1.22 (1.01 to 1.48) 
Källén et al 2013 
 
Any ASM Asthma 0.063 Reported in the same paper 
(Källén et al 2013) 
 
1.60 (1.40 to 1.76) 1.54 (1.37 to 1.68) 




Any ASM Asthma 0.11 Based on Mulder et al 2014
5 
 
1.85 (1.07 to 3.19) 1.69 (1.06 to 2.57) 




Any ASM Asthma 0.11 Based on Mulder et al 2014
5
 1.52 (1.11 to 2.10) 1.44 (1.10 to 1.87) 
1
Reference 9. The same formulae was used for converting the lower and upper 95% confidence intervals as suggested by Robert Grant in an electronic correspondence 
2
Abbreviations: ASM  Acid-suppressive medications; H2RA  H2- receptor antagonists; PPI  Proton pump inhibitors 
3
Mulder et al 2013 undertook two sets of analysis using the same asthma cases but different controls the same study and compared estimates from analyses: Mulder et al 
2013a use siblings of the cases as the controls while Mulder et al 2013b used non-sibling as controls. Hence each analysis was regarded as independent on its own right given 


















































Figure E1 PRISMA flow diagram for database search of studies investigating the association 
between maternal use of acid-suppressive medications during pregnancy and risk of asthma and 
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Ethics approval 32 
We completed the University of Edinburghs Usher Institute of Informatics and Population Health 33 
Sciences Level 1 Ethics Clearance, which revealed that no further ethics clearance is required 34 
since the study is based on the published literature. 35 
 36 
Protocol and registration 37 
Prior to commencement of the review, we developed a detailed protocol, which was published1 and 38 
registered with the International Prospective Register of Systematic Reviews (PROSPERO; 39 
http://www.crd.york.ac.uk/prospero/, reference CRD42015029584). 40 
 41 
Eligibility criteria 42 
We included analytical epidemiological studies, i.e. cohort, case-control, and cross-sectional 43 
studies. We excluded reviews, case studies and case series, and animal studies. All women during 44 
preconception and pregnancy and their offspring who were 17 years were eligible for inclusion. 45 
 46 
Types of exposure 47 
We considered all studies that investigated the association between maternal use of any type of 48 
acid-suppressive medications (H2RA, PPIs, and antacids) during pregnancy and the risk of asthma 49 
and allergy in the offspring. We also considered the dose, frequency, and timing (trimester) of use 50 
of these medications. 51 
 52 
Study outcomes 53 
Our primary outcomes were objectively defined asthma, atopic dermatitis/eczema, allergic rhinitis 54 
or hay fever, anaphylaxis, food allergy, urticaria and anaphylaxis by physician or hospital record or 55 
self-reported; and atopic sensitization as defined either by skin prick test or raised antigen specific 56 
IgE. Secondary outcomes included objective and subjective measures of disease severity and 57 
impact on quality of life, including asthma exacerbations, use of asthma medications, 58 
hospitalization for asthma, wheeze as defined by self-report or objective diagnosis; indicators of 59 
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airway function including (peak expiratory flow [PEF], forced expiratory volume in 1 second [FEV1], 60 
forced vital capacity [FVC], forced expiratory flow rate or alternative age appropriate pulmonary 61 
function tests [oscillometry or exhaled nitric oxide analysis]); and measures of health related quality 62 
of life.  63 
 64 
Information sources, search strategy and study selection 65 
We searched the following international electronic databases: MEDLINE, EMBASE, Web of 66 
Science CORE, BIOSIS, CINAHL, Cochrane Library, Global Health CABI, Global Health Library, 67 
Scopus, Popline and Google Scholar. Additional studies were retrieved by manual search of the 68 
references of eligible papers and by contacting a panel of international experts on the topic. 69 
Conference abstracts were retrieved by searching ISI Conference Proceedings Citation Index via 70 
Web of Knowledge and ZETOC (British Library).  Unpublished and in-progress studies were 71 
identified by searching Current Controlled Trials, ClinicalTrials.gov, Australian and New Zealand 72 
Clinical Trials Registry. We developed a detailed search strategy in MEDLINE, which was then 73 
adapted in searching other databases (Table E1). All databases were searched from inception to 74 
the end of 2015, with no language restrictions.  Identified records were exported to Endnote Library 75 
for screening. After removal of duplicate records, two reviewers (RD and BN) independently 76 
screened all titles and/or abstracts. Full texts of potentially eligible studies were obtained and 77 
independently screened for inclusion by the two reviewers. Studies that did not fulfil the inclusion 78 
criteria were excluded. Any discrepancies in the screening process were resolved by discussion. 79 
 80 
Data extraction and quality assessment 81 
Two reviewers (RD and BN) independently extracted study data onto a customized data extraction 82 
form. The data extraction form was piloted and revised prior to use in collecting data from all 83 
studies. Discrepancies in data extraction were resolved by discussion and arbitration by a third 84 
reviewer (NM). The PRISMA checklist guided reporting.2  85 
 86 
Risk of bias in individual studies 87 
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Two reviewers (RD and BN) independently undertook the risk of bias analysis in the study using 88 
the Effective Public Health Practice Project tool, which was adapted for use in this review. We 89 
graded key components of each study as strong, moderate, or weak: suitability of the study design 90 
for the research question; validity of exposure and outcome assessments; potential for selection 91 
bias; and appropriate adjustment for confounding factors. From these component-specific 92 
assessments, we derived an overall grading for each study as strong, moderate, or weak. Any 93 
discrepancies were resolved by discussion or a third reviewer (NM) arbitrated. 94 
 95 
Summary measures 96 
Eligible studies reported one of the following effect measures: hazard ratio (HR), risk ratio (RR), or 97 
odds ratio (OR). Although Andersen et al3 stated that they estimated incidence rate ratios using 98 
Cox proportional hazard regression, we took these estimates as HR in the pooled analysis 99 
because the Cox model estimates the hazard function. Mulder et al10 and Soriano et al12 also 100 
reported HR. Yitshak-Sade et al4  reported RR; estimates of studies reporting OR5,6-8 were 101 
converted to RR using the formulae by Grant9 and then pooled with the Yitshak-Sade et al4 study. 102 
The formulae for conversion is given as follows: RR = OR/(1-p0+(p0 x OR)); where p0 is the 103 
baseline risk. The baseline risks for Dehlink et al5 and Källén et al6 were taken from the respective 104 
papers. The baseline risk for Mulder et al 20137 was taken from Mulder et al 2014,10 which was 105 
based on the same study population. For Hak et al,8 we used the prevalence estimate (4.2%) 106 
reported elsewhere but based on a similar primary care database.11 The RR derived from these 107 
calculations are presented in Table E5. 108 
 109 
Data synthesis 110 
Of the eight studies, six were retrospective cohort studies,3-6,10,12 while two were case-control 111 
studies.7,813,14 We summarized the overall evidence both narratively and quantitatively. For the 112 
quantitative synthesis, we employed random-effects meta-analysis to quantify the pooled effect 113 
estimates for sufficiently clinically, methodologically, and statistically homogeneous studies. Mulder 114 
et al 20137 analyzed two sets of control populations that were compared to the same asthma 115 
cases: sibling-based controls and non-sibling-based controls. In the analysis, we treated these sets 116 
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of case-control populations independently. This was applicable for use of any acid-suppressive 117 
medications, H2RA only, and PPIs only; there were no data on use of antacids. Dosage of acid-118 
suppressive medications and trimester of exposure were differentially reported across studies, 119 
hence we were unable to pool studies on these exposures. Meta-analysis was possible only with 120 
studies on asthma and not for other outcomes as an insufficient number of studies were available 121 
for other allergic outcomes. In the meta-analysis, studies reporting HR and RR were separately 122 
pooled. We quantified the level of heterogeneity between studies using the I2 statistic. In addition to 123 
the overall summary effect estimate, we also estimated the 95% prediction interval, which takes 124 
into account the overall uncertainty surrounding the summary effect and heterogeneity across 125 
studies to provide a range for which we are 95% confident that the effect of acid-suppressive 126 
medications on the risk of asthma in new studies would lie.13 Given that the number of studies for 127 
each meta-analysis was small, thus lacking the required power (i.e less than the recommended 128 
minimum of 10 studies),14 we were unable to graph the funnel plots to evaluate possible publication 129 
bias or small study effect; hence we performed the Begg and Egger tests for this purpose.15 Meta-130 
analyses were undertaken using Stata Statistical Software: Release 14. College Station, TX: 131 
StataCorp LP. 132 
 133 
Sensitivity analyses 134 
Given observed high heterogeneity across studies in the meta-analysis of the association between 135 
use of any ASMs or H2RA/PPIs, we undertook the following steps to explore possible reasons for 136 
the heterogeneity: first, we stratified the analysis by study design (cohort vs case-control studies); 137 
second, given that within the cohort studies, in comparison to other studies, the study by Yitshak-138 
Sade et al 2015 studied use of H2RA or PPIs rather than use of any acid-suppressive medications, 139 
we excluded that study to assess its impact on the heterogeneity across studies. 140 
 141 
Grading the quality of the overall body of evidence 142 
Using the GRADE system, we first identified all potentially relevant outcomes and rated their 143 
relative clinical importance: asthma was considered a critical outcome; atopic dermatitis/eczema, 144 
allergic rhinitis, and other allergic disorders were considered as important outcomes. Second, we 145 
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appraised the quality of the overall evidence for each outcome and presented this information 146 
using the GRADE evidence profiling table template.16 147 
 148 
RESULTS 149 
Study selection 150 
We identified 3282 records, of which 3057 were included for screening by title and/or abstract after 151 
de-duplication. Of these, 3033 were excluded for not meeting the inclusion criteria, leaving 24 152 
papers for full text screening. A further 16 papers were excluded, leaving eight papers that met our 153 
inclusion criteria (Figure E1).3-8,10,12 154 
 155 
Study characteristics 156 
All studies were either based on a primary care database or population-based prescription or 157 
dispensing database. Two studies each were undertaken in The Netherlands7,10 Sweden5,6 and 158 
United Kingdom,8,12 whereas one study each was undertaken in Denmark3 and Israel.4 All studies 159 
considered asthma as an outcome while two in addition considered other allergic disorders, 160 
including atopic dermatitis/eczema and allergic rhinitis.5,10 Whereas most studies considered use of 161 
any acid-suppressive medication or H2RA/PPIs,5-8,10 the independent role of H2RA and PPIs were 162 
examined in three studies,3,4,10 but no study examined the role of antacids alone. Seven of the 163 
studies also considered the trimester of exposure to acid-suppressive medications, while three 164 
examined the dosage of use, commonly defined as defined daily doses; however, marginally 165 
different definitions of trimester and dosage were used across studies. 166 
 167 
Risk of bias within studies 168 
Based on overall risk of bias assessment in the studies, six studies were graded as strong and two 169 
as moderate. The overall quality grading was derived from the grading for the different components 170 
of the studies. Apart from Mulder et al7, which was graded weak for confounding adjustment, all 171 
other studies were graded moderate or strong for all components (Table E3). 172 
 173 
Use of acid-suppressive medications and risk of asthma 174 
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Across individual studies, offspring of mothers who used any acid-suppressive medications during 175 
pregnancy were at an increased risk of asthma compared to offspring of non-users (Table E2). The 176 
results were similar when H2RA and PPIs were examined separately, except for imprecise 177 
estimates from two studies.10,12 Higher dosage of acid-suppressive medications  appeared to show 178 
a greater risk compared to lower dosage (Table E2). Whereas use of acid-suppressive medications 179 
during any trimester of pregnancy was associated with an increased risk of asthma, there was no 180 
clear indication that any specific trimester was associated with greatest risk (Table E2). The high 181 
heterogeneity in the analysis of the use of any acid-suppressive medications was reduced in 182 
further exploration, as explained in the sensitivity analysis section. 183 
 184 
Use of ASMs and risk of other allergic disorders 185 
The association between use of acid-suppressive medications and other allergic disorders was 186 
investigated by two studies,5,10 both reporting an increased risk amongst offspring of mothers using 187 
any acid-suppressive medications, H2RA, and PPIs, compared to those of non-using mothers 188 
(Table E2). Mulder et al10 in addition reported an increased risk of atopic dermatitis/eczema and 189 
allergic rhinitis with use of acid-suppressive medications, although estimates were imprecise in 190 
some cases for the independent roles of H2RA and PPIs (data not shown). Given the different 191 
effect measures used by Dehlink et al5 (OR) and Mulder et al10 (HR), and considering that only 192 
Mulder et al 2014 examined atopic dermatitis/eczema and allergic rhinitis, we could not calculate 193 
pooled estimates of the association between acid-suppressive medications and risk of allergic 194 
disorders other than asthma.  195 
 196 
Sensitivity analyses 197 
By stratifying the association between use of any acid-suppressive medication or H2RA/PPIs by 198 
study design the results showed that the high heterogeneity was specific to the cohort studies 199 
(Figure 1). Further exclusion of the study by Yitshak-Sade et al4 reduced the heterogeneity in all 200 
studies from the initial 87% to 18% and the heterogeneity in the cohort studies from 95% to 0% 201 
(Figure 1). Stratification of the results by study design and exclusion of the Yitshak-Sade et al 202 
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study4 did not dramatically change the pooled relative effect estimates, but did result in a more 203 
precise predictive interval (1·23-1·75) (Figure 1). 204 
 205 
Grading quality of the overall body of evidence 206 
By applying the GRADE system (Table E4), we graded the evidence regarding risk of asthma as 207 
moderate. None of the studies assessed the possible influence of confounding by indication, 208 
unmeasured confounding, and acid-suppressive medications data were based on either prescribed 209 
or dispensed medication without information on actual use. It is therefore possible that the results 210 
could be partly explained by these factors. Given very few studies, we graded the evidence 211 
regarding atopic dermatitis/eczema, allergic rhinitis, and other allergic outcomes as very low.  212 
 213 
Assessment of publication bias 214 
We calculated the Eggers test for the association between use of any acid-suppressive 215 
medications and risk of asthma and the result showed P=0.415 (Table E5), indicating that 216 
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